How has AstraZenca Pharma India Ltd. (ASTRAZEN) been performing? We dig into revenue, profitability, valuation, and ownership trends.
AstraZenca Pharma Revenue Trend
AstraZenca Pharma India Ltd. clocked ₹1,757 Cr in revenue for FY2025, up 32.1% from FY2024.
AstraZenca Pharma India Ltd.'s revenue grew from ₹517 Cr to ₹1,757 Cr at a 13.0% CAGR over 10 years — a pace most companies would be happy with.
With a top line of ₹1,757 Cr, AstraZenca Pharma India Ltd. operates at a mid-sized scale within the pharmaceuticals sector.
The consistency stands out: 3 consecutive years of growth in top-line revenue.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,757 Cr | +32.1% |
| FY2024 | ₹1,330 Cr | +29.3% |
| FY2023 | ₹1,029 Cr | +25.4% |
| FY2022 | ₹820 Cr | -0.7% |
| FY2021 | ₹826 Cr | — |
View AstraZenca Pharma India Ltd.'s full 10-year revenue trend with CAGR analysis →
AstraZenca Pharma Profitability
At ₹116 Cr, AstraZenca Pharma India Ltd.'s FY2025 net profit was 28.3% below what it earned in FY2024.
The company's net margin contracted to 6.6% in FY2025 from 12.1% in FY2024.
The diluted EPS figure moved down to ₹46.30 in FY2025, against ₹64.60 posted in FY2024.
Is AstraZenca Pharma Undervalued
The P/E Ratio approach puts AstraZenca Pharma India Ltd.'s intrinsic value at ₹5,467, a 36.1% downside from the current market price.
AstraZenca Pharma India Ltd. shares are currently trading at ₹8,557.00.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹5,467 | 36.1% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for AstraZenca Pharma India Ltd. with detailed assumptions →
AstraZenca Pharma Shareholding Pattern
Promoters haven't moved — their 75.0% holding has been unchanged for 4 quarters.
Foreign institutional investors (FIIs) held 2.8% as of March 2026, down from 3.0% a year ago.
Domestic institutions moved their stake up to 5.8% from 4.6% over the past year.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 75.0% | 2.8% | 5.8% | 16.4% |
| Dec 2025 | 75.0% | 2.7% | 5.6% | 16.7% |
| Sep 2025 | 75.0% | 2.7% | 5.3% | 17.0% |
| Jun 2025 | 75.0% | 3.0% | 4.6% | 17.4% |
Track quarterly shareholding changes for AstraZenca Pharma India Ltd. →
AstraZenca Pharma Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹15.18B (up 40.8% YoY from ₹10.78B).
Top categories: Inventories (36.1%), Cash & ST Investments (35.4%), Other Assets (14.5%).
Of the ₹15.18B in liabilities and equity, 50.7% is shareholder equity, 2.4% is interest-bearing debt, and 46.9% is operating liabilities. Over the year, debt is up 678.4% and equity is up 8.2%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 5.37B |
| Receivables | 1.85B |
| Inventories | 5.49B |
| Property, Plant & Equipment | 278.80M |
| Intangibles & Goodwill | 6.60M |
| Other Assets | 2.20B |
| Category | Value |
|---|---|
| Equity | 7.70B |
| Short-term Debt | 62.80M |
| Long-term Debt | 294.50M |
| Trade Payables | 4.56B |
| Other Liabilities | 2.56B |
AstraZenca Pharma at a Glance
Pulling it all together, here's what the numbers say about AstraZenca Pharma India Ltd. (ASTRAZEN) heading into the next fiscal year.
Revenue of ₹1,757 Cr in FY2025, up 32.1% year-over-year.
Long-term revenue has been compounding at 13.0% annually over 10 years.
The company is profitable, with a net margin of 6.6% and net income of ₹116 Cr.
The P/E Ratio model implies 36.1% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for AstraZenca Pharma India Ltd. includes three valuation models, decade-long financials, and insider activity.